Business Description
Guangdong Hybribio Biotech Co Ltd
ISIN : CNE100002N51
Share Class Description:
SZSE:300639: Class ACompare
Compare
Traded in other countries / regions
300639.China IPO Date
2017-04-12Description
Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.63 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5.83 | |||||
| Beneish M-Score | -3.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.8 | |||||
| 3-Year EBITDA Growth Rate | -22.4 | |||||
| 3-Year EPS without NRI Growth Rate | -29.7 | |||||
| 3-Year Book Growth Rate | 27.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.04 | |||||
| 9-Day RSI | 48.88 | |||||
| 14-Day RSI | 51.44 | |||||
| 6-1 Month Momentum % | 12.3 | |||||
| 12-1 Month Momentum % | -35.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.55 | |||||
| Quick Ratio | 6.32 | |||||
| Cash Ratio | 2.38 | |||||
| Days Inventory | 95.65 | |||||
| Days Sales Outstanding | 768.08 | |||||
| Days Payable | 122.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.96 | |||||
| Dividend Payout Ratio | 0.66 | |||||
| 3-Year Dividend Growth Rate | 70.2 | |||||
| Forward Dividend Yield % | 0.96 | |||||
| 5-Year Yield-on-Cost % | 4.93 | |||||
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | 2.64 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.32 | |||||
| Operating Margin % | -17.9 | |||||
| Net Margin % | -33.97 | |||||
| FCF Margin % | -1.9 | |||||
| ROE % | -6.17 | |||||
| ROA % | -5.27 | |||||
| ROIC % | -3.07 | |||||
| ROC (Joel Greenblatt) % | -18.09 | |||||
| ROCE % | -10.66 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 24.96 | |||||
| PE Ratio without NRI | 67.98 | |||||
| Shiller PE Ratio | 11.22 | |||||
| PEG Ratio | 2.08 | |||||
| PS Ratio | 4.82 | |||||
| PB Ratio | 0.97 | |||||
| Price-to-Tangible-Book | 1.04 | |||||
| Price-to-Free-Cash-Flow | 2243.34 | |||||
| Price-to-Operating-Cash-Flow | 21.34 | |||||
| EV-to-EBIT | -6.35 | |||||
| EV-to-EBITDA | -6.35 | |||||
| EV-to-Revenue | 3.98 | |||||
| EV-to-FCF | -196.46 | |||||
| Price-to-Projected-FCF | 1.03 | |||||
| Price-to-DCF (Earnings Based) | 2.18 | |||||
| Price-to-DCF (FCF Based) | 224.33 | |||||
| Price-to-Graham-Number | 1.77 | |||||
| Price-to-Net-Current-Asset-Value | 2.3 | |||||
| Price-to-Net-Cash | 14.32 | |||||
| Earnings Yield (Greenblatt) % | -15.75 | |||||
| FCF Yield % | -0.38 | |||||
| Forward Rate of Return (Yacktman) % | 22.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guangdong Hybribio Biotech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 864.068 | ||
| EPS (TTM) (Â¥) | -0.421 | ||
| Beta | 0.77 | ||
| Volatility % | 50.43 | ||
| 14-Day RSI | 51.44 | ||
| 14-Day ATR (Â¥) | 0.368992 | ||
| 20-Day SMA (Â¥) | 6.531 | ||
| 12-1 Month Momentum % | -35.19 | ||
| 52-Week Range (Â¥) | 4.32 - 10.08 | ||
| Shares Outstanding (Mil) | 646.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guangdong Hybribio Biotech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guangdong Hybribio Biotech Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guangdong Hybribio Biotech Co Ltd Frequently Asked Questions
What is Guangdong Hybribio Biotech Co Ltd(SZSE:300639)'s stock price today?
The current price of SZSE:300639 is ¥6.73. The 52 week high of SZSE:300639 is ¥10.08 and 52 week low is ¥4.32.
When is next earnings date of Guangdong Hybribio Biotech Co Ltd(SZSE:300639)?
The next earnings date of Guangdong Hybribio Biotech Co Ltd(SZSE:300639) is .
Does Guangdong Hybribio Biotech Co Ltd(SZSE:300639) pay dividends? If so, how much?
The Dividend Yield %  of Guangdong Hybribio Biotech Co Ltd(SZSE:300639) is 0.96% (As of Today), Highest Dividend Payout Ratio of Guangdong Hybribio Biotech Co Ltd(SZSE:300639) was 1.75. The lowest was 0.07. And the median was 0.22. The  Forward Dividend Yield % of Guangdong Hybribio Biotech Co Ltd(SZSE:300639) is 0.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers